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Introduction
Chronic pulmonary aspergillosis is a rather uncommon 
disease often affecting patients with prior or current 
pulmonary disease. These patients are usually non-
immunocompromised or mildly immunocompromised (1). 
The morphological appearance of a fungal ball which 
typically forms in a pre-existing pulmonary cavity due 
to saprophytic colonization of Aspergillus consists almost 
entirely of fungal hyphae and extracellular matrix and is 
called pulmonary aspergilloma. Several forms of chronic 
pulmonary aspergillosis can occur with an aspergilloma. 
Belcher and Plummer in 1960 classified aspergillomas 
as simple or complex, in which simple aspergilloma is a 
single fungal ball in a single pulmonary cavity that does 
not progress over months and causes few or no symptoms; 
serological evidence of Aspergillus may be absent (2,3). 
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Contemporary terminology for complex aspergilloma is 
chronic cavitary pulmonary aspergillosis (CCPA). CCPA 
is associated with high morbidity and mortality (1,4,5) 
and results of surgical resection of an aspergilloma in 
CCPA, compared with those for simple aspergilloma, are 
considerably worse (2,6-8). 
When a pulmonary cavity with an aspergilloma 
exists, this can result in repetitive haemosputum or life-
threatening massive haemoptysis (4,9-11) and results 
of antifungal treatment are usually disappointing (12). 
Spontaneous lysis of an aspergilloma happens occasionally, 
and occurs in 5% to 10% of cases (13,14). Options for 
treating haemoptysis are either radiological embolization of 
artery or surgical resection; the latter, however, is the only 
option for curative treatment. The surgical procedure can 
often be challenging due to ongoing inflammatory process 
resulting in formation of intrathoracic adhesions, and the 
risk for postoperative complications remains high (2,15). 
Selecting the right patients for surgical treatment is thus 
crucial. Despite several decades’ experience, the indications 
remain somewhat unclear as does optimal use of antifungal 
treatment combined with surgery. 
Here, we evaluated the background and the clinical and 
surgical long- and short-term outcome of patients who 
underwent surgery for pulmonary aspergillosis in Helsinki 
University Central Hospital between 2004 and 2017. The 
aim was to analyze early and long-term results of surgical 
treatment for pulmonary aspergilloma.
Methods
Study population
From 2004 to 2017, 22 patients underwent surgery for 
pulmonary aspergilloma in Helsinki University Hospital 
and we retrospectively assessed their clinical and surgical 
characteristics. Patient identification in the hospital registry 
utilized ICD-codes B44.0 to B44.9. All the data came from 
hospital database and medical records. We examined their 
clinical backgrounds: age, gender, underlying pulmonary 
disease, immunosuppressive medication or other cause of 
immunosuppression, Aspergillus-related laboratory findings, 
pulmonary function test results, anti-fungal medication 
(if any) and its duration pre- and postoperatively, and 
indication for surgery. We assessed peri- and postoperative 
results:  operative procedure, duration of surgery, 
intraoperative blood loss, use of omentum or latissimus 
dorsi to fill the remaining empty space during surgery, 
perioperative complications, duration of hospital stay, 
postoperative complications, recovery from surgery, 
recurrent Aspergillus infection, survival, and reason of death 
if not alive in October 2018. 
The study protocol was approved by the research board 
of the Heart and Lung Centre of Helsinki University 
Hospital.
Results
Clinical characteristics 
Of the 22 patients 14 were male, 8 female, mean age 56 
[37–75]. An underlying pulmonary disease was evident 
in 20, but 2 patients showed no respiratory disease. 
Underlying pulmonary diseases and comorbidities are listed 
in Table 1. The most common pulmonary conditions were 
asthma (7 patients) and COPD (5 patients). A pre-existing 
Table 1 Patient characteristics
Characteristic Number
Total number of patients 22
Age, median 56 [37–75]
Gender (n)
Male 14
Female 8
Pulmonary disease (n)
Asthma 7
COPD 5
Previous tuberculosis 5
Other previous infection 2
Pneumothorax 2
Emphysema 1
Previous aspergilloma 1
Comorbidities (n)
Rheumatological disease 6
Malignancy (current or previous) 5
Diabetes mellitus 2
Chronic neutropenia 2
Stem cell transplantation 2
Solid organ transplant 1
Alcohol abuse 1
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pulmonary cavity apparent in previous thoracic X-ray was 
evident in 11 patients. Other common co-morbidities 
included rheumatological diseases—rheumatoid arthritis 
or ankylosing spondylitis—and elevated blood pressure. 
Of the two patients with no any evident lung disease one 
had chronic idiopathic non-immunological neutropenia, 
collagenosis and immunosuppressive treatment; the other 
only elevated blood pressure as a diagnosed co-morbidity. 
Immunosuppression 
At diagnosis, eight (36%) patients received immunosuppressive 
treatment (more than 5 mg prednisolone daily). Four of 
them received medication for rheumatological disease, 
one due to liver transplantation, one had immunological 
neutropenia and high-dose steroid treatment, one received 
repeated steroid courses for asthma, and one had undergone 
an allogenic stem cell transplantation due to Hodgkin 
disease and was suffering graft-versus-host disease (GVHD). 
Diabetes mellitus type II was the diagnosis in two patients 
and one was known to abuse alcohol. Five patients had 
previous or current malignant disease. One of them 
underwent surgery for aspergilloma prior to chemotherapy 
for oesophageal carcinoma, one had Hodgkin disease and 
allogenic stem cell transplantation, one patient had been 
operated on breast cancer and one for renal carcinoma, and 
one patient had suffered mediastinal embryonal carcinoma 
and undergone autological stem cell transplantation. These 
malignancies were considered cured, except for the case 
of oesophageal carcinoma. Among the 8 patients receiving 
immunosuppressive medication 6 had single aspergilloma 
and no evidence of progressive disease. Two of these 
patients had more than one nodule at the time of diagnosis.
Preoperative lung function
Lung-function test results were available in all but one 
patient preoperatively. Average forced vital capacity (FVC) 
as percent of predicted was 85% (range, 30–113%) and 
average forced expiratory volume in one second (FEV1) as 
percent of predicted was 78 % (range, 20–114%). Diffusion 
capacity results were available for 16 patients, with average 
diffusion capacity as percent of predicted being 74% (range, 
52–112%).
Diagnosis
Radiological findings usually raised suspicion of an 
aspergilloma. Radiological images of three of our patients 
can be seen in Figures 1-3. Radiological findings were not 
quite typical in all cases, but Aspergillus was suspected to 
be the cause. In 6 cases Aspergillus-positive sputum culture 
together with radiological findings and in 4/6 patients also 
elevated Aspergillus fumigatus IgG-levels was considered to 
be sufficient evidence of aspergilloma. If sputum samples 
were negative or unavailable, or radiology suggestive of 
another diagnosis, further examinations were carried out. 
Bronchoscopy with bronchoalveolar lavation was performed 
Figure 1 A 62-year-old male with history of pulmonary tuberculosis. Simple aspergilloma. No immunosuppression. Lobectomy of right 
upper lobe.
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Figure 2 A 51-year-old female with history of pulmonary tuberculosis, grossly destroyed right lung. No immunosuppression. Hemoptysis. 
Pulmectomy of right lung. 
Figure 3 A 48-year-old male with history of asthma, no immunosuppression. Hemoptysis. (A) Before operation (lobectomy of right upper 
lobe); (B) recurrence in right lower lobe.
BA
for 7 patients to obtain samples for culture, and they turned 
out to be positive for Aspergillus in 3/7. Samples for culture 
were obtained by CT-guided biopsy in 10 cases, however 
in three cases it did not confirm the diagnosis. Among 
the 22 patients, 16 (73%) had a preoperative diagnosis of 
pulmonary aspergillosis by culture. Two of the patients 
having no positive cultures before surgery had elevated 
blood Aspergillus fumigatus IgG and IgE levels. Aspergillus 
fumigatus IgG levels in blood were elevated in 8 of our 
patients but had been analysed only in 10; Aspergillus 
fumigatus IgE—levels had been analysed in 9 patients and 
proved to be elevated in 5. In four cases, any microbiological 
or serological evidence of Aspergillus before surgery was 
absent. Despite missing verification of Aspergillus-disease 
these patients went through operation either because the 
suspicion of such disease was strong, or malignancy was 
considered to be possible diagnosis. 
Histopathological tissue samples taken during surgery 
confirmed the diagnosis, with species growing in culture 
being Aspergillus fumigatus in all cases. Susceptibility testing 
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results were available in eight (36%) cases. No resistance 
against voriconazole was detectable, but susceptibility to 
posaconazole was lowered in two and to itraconazole in two 
cases.
Several of these aspergillomas treated surgically had 
formed in previously severely destroyed lung tissue, 
but with no evident Aspergillus in the surrounding lung 
parenchyma reported by the pathologist postoperatively; in 
most cases aspergillomas had remained stable for months 
prior to surgery. Thus, according to diagnostic criteria of 
CCPA as presented by Denning et al. (3,16), the majority of 
our surgical patients did not have CCPA. In retrospective 
analysis CCPA-patients suffering from progressive disease 
accounted for 32% (7/22) of these surgical patients. 
One patient had two sites of a suspected aspergilloma 
preoperatively, in others only one site—but in some cases 
in largely destroyed lung parenchyma—was detected 
preoperatively. 
Operative indications and procedures 
Reasons for referring the patient for surgery included 
haemoptysis, recurrent infections, or an indefinite 
radiological finding. Indication for surgery was haemoptysis 
in 10 (45%) patients. Other symptoms of infection or 
recurrent infections were the indication in eight (36%) 
patients, two of whom had bronchopleural fistulae. In one 
patient an aspergilloma was evident in a CT scan while 
diagnosing oesophageal carcinoma, and he underwent 
surgery prior to chemotherapy to reduce the risk of 
fulminant fungal infection during immunosuppression. 
Three patients were asymptomatic but had a thoracic X-ray 
for other reasons. In one case, the X-ray was very typical 
for simple aspergilloma but in the other two Aspergillus 
was considered a possible cause of an indefinite finding in 
a CT scan, but also preoperatively considered as possible 
diagnosis were an abscess caused by another infective agent 
or a malignancy. 
The thoracic surgeon decided on surgical technique and 
extent. When only a small lesion of 3 cm or less existed, 
a wedge-resection or segmentectomy was the choice. 
Lobectomy occurred for any larger infiltration if lung 
capacity was sufficient, and in one case pulmonectomy was 
necessary because the lung was severely destroyed due to 
previous tuberculosis and scarring. If the remaining empty 
space needed filling, the surgeon decided whether to use 
latissimus dorsi flap or omentum during the operation. 
According to medical records, no intraoperative spillage of 
Aspergillus into the pleural cavity occurred in any of these 
procedures. 
The surgical procedures are listed in Table 2. One patient 
had video-assisted thoracoscopy (VATS) operation but in all 
other cases thoracotomy was performed. 
Antifungal treatment
Most patients (12, 55%) used antifungal medication prior 
to surgery. In clinical practice, medication schemes were 
diverse. The preoperative-medication period ranged from 
3 weeks to 39 months. Most patients received treatment 
postoperatively (19, 86%), the suggested length of the 
medication varied from 1 to 6 months and in cases of 
recurrent infection or suspected CCPA or ABPA (allergic 
bronchopulmonary aspergillosis) continued until death or 
was considered long term or permanent. Some patients, 
however, continued the medication for an indefinite time 
period even after surgery, with the medication stopped 
only when considerable side-effects occurred. Voriconazole 
was the most commonly used antifungal medication, 
but some patients received itraconazole or posaconazole 
instead. Four patients (18%) received i.v. treatment peri- or 
postoperatively with either amphotericin-B or caspofungin. 
Three patients (14%) received no antifungal treatment pre- 
or postoperatively, because surgery was considered sufficient 
therapy.
Complications
No perioperative mortality occurred, and no mortality 
Table 2 Surgical procedure
Operative characteristics No. of patients
Lobectomy only 9
With segmentectomy 2
Wedge resection only 2
With segmentectomy 1
Segmentectomy only 6
Pneumonectomy 1
Fenestration and resection 1
Operative time (minutes), median 210 [23–559]
Intraoperative blood loss (mL), median 400 [30–4,380]
Postoperative hospital stay (days), median 12 [6–42]
4303Journal of Thoracic Disease, Vol 11, No 10 October 2019
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(10):4298-4307 | http://dx.doi.org/10.21037/jtd.2019.09.48
within 30 days post-operatively. One in-hospital death, 
however, occurred; on day 42 one patient died from 
postoperative complications—he had prolonged air leak 
and pneumonia and had remained in ICU since surgery. 
Other postoperative complications included prolonged air 
leak for over 7 days in five patients (23%), pneumothorax 
occurring after hospital discharge in two (9%) and 
pneumomediastinum in one (5%), and postoperative 
pneumonia in five (23%) patients. No postoperative 
pleuritis or Aspergillus empyema occurred. 
Recurrent disease
Recurrent Aspergillus infection has been confirmed in four 
patients (18%) after their surgery. One of them underwent 
surgery as a palliative procedure because he had recurrent 
Aspergillus disease (after initial aspergilloma operation in 
2001). He was evidently suffering from CCPA and died 
from Aspergillus infection 6 months after palliative surgery. 
The three other patients in whom recurrent Aspergillus 
disease occurred were all asthma patients with elevated 
Aspergillus-IgE-levels and all were suffering from ABPA and 
possibly CCPA; some overlapping and transition in these 
diseases occur (17,18). 
None of the three asthma patients who had history of 
ABPA were on continuous corticosteroid treatment during 
or shortly prior to the operation. The indication for surgery 
was haemoptysis on one of these patients, one had been 
treated for three years with antifungals but she developed 
bronchopleural fistulae and was operated to control the 
infection. The third one of these patients also had history 
of recent renal carcinoma and possibility of pulmonary 
metastasis supported the decision to operate. 
In all these three patients a radiologically evident new 
aspergilloma has formed in a pulmonary cavity after the 
initial operation. 
Survival
During the subsequent follow-up until October 2018, of 
the 22 patients 10 (45%) died. During the first year after 
surgery three patients (14%) died: one of postoperative 
complications, one of oesophageal carcinoma that he 
already had at the time of surgery, and one of Aspergillus 
infection six months after palliative surgery.
All the other 19 (86%) patients were alive 20 months 
after surgery. The last of the operations evaluated took place 
in February 2017. Five-year survival could be evaluated in 
13 of the 22. Six out of 13 (46%) died within five years of 
the surgery including the 3 deaths occurring within one 
year, 5-year survival is presented in Figure 4. The reasons 
for death of the 10 patients who died, included pulmonary 
fibrosis associated with rheumatoid arthritis, lung cancer 
(3 patients), and GVHD after Hodgkin disease and 
allogenic stem cell transplantation. In two cases the reason 
of death could not be concluded from the medical records. 
In Table 3 are presented the patient characteristics and 
reasons for death. Only two deaths appear to be related to 
Aspergillus-disease. 
Discussion
In our post-operative cohort, the recurrence rate of 
Aspergillus—infection was low. Interestingly, all the recurrent 
infections in this small group appeared in asthmatics who 
suffered from ABPA or CCPA and ABPA. All these three 
patients had cavitary disease with progression although the 
history of asthma, elevated total IgE and Aspergillus IgE-
levels suggested the diagnosis of ABPA. 
Short-term results of surgery were good, all but one 
patient surviving the immediate postoperative period. Only 
one other patient died of recurrent pulmonary aspergillosis, 
but the indication for his surgery was palliation instead of 
cure. Other postoperative deaths cannot be considered the 
result of Aspergillus disease.
Most surgical patients had normal or nearly normal 
preoperative lung function. Careful selection of patients for 
surgery has probably resulted in their good overall outcome 
and few recurrent infections.
The wide variety of surgical procedures ranged from 
pneumonectomy to palliative fenestration. Surgical 
procedures were time-consuming, and the postoperative 
hospital stay was often prolonged. Within four weeks 
patients recovered well, however, and most of them were 
cured. The number of complications was reasonable, and no 
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Table 3 Patient characteristics, in chronological order of surgery 2004–2017
Age Sex Underlying disease Type of operation
Preoperative 
medication
Postoperative 
medication
Survival/time Reason of death
59 M COPD Lobectomy None voriconazole, 
amphotericin-B
Dead, 24 days postoperative 
pneumonia
50 M COPD, rheumatoid arthritis Lobectomy None voriconazole, 
itraconazole
Dead, 1 y 23 mt pulmonary fibrosis 
associated to RA
73 F Childhood pneumonia Segmentectomy Voriconazole Voriconazole Dead, 8 yrs Pulmonary carcinoma
62 M Tbc Lobectomy Voriconazole Voriconazole Alive
57 M Asthma, previous 
aspergilloma operation, 
ankylosing spondylitis
Fenestration, 
pulmonary 
resection
Voriconazole Posaconazole Dead, 6 mt CCPA
53 M Pneumothorax, 
oesophageal carcinoma
Segmentectomy None Voriconazole Dead, 4 mt Oesophageal 
carcinoma
71 F Collagenosis, chronic non-
immunologic neutropenia
Lobectomy Voriconazole Voriconazole Dead, 7 y 3 mt Unknown
43 M Mediastinal embryonal 
carcinoma, autologic stem 
cell transplantation
Lobectomy and 
segmentectomy
Voriconazole Voriconazole Dead, 3 yrs Pulmonary carcinoma
75 F COPD, emphysema, 
immunological neutropenia, 
diabetes, breast cancer
Lobectomy Voriconazole Caspofungin, 
voriconazole
Dead, 8 y 5 mt Pulmonary carcinoma
61 F Tbc, COPD, rheumatoid 
arthritis
Segmentectomy None Voriconazole Alive
48 M Asthma Lobectomy Voriconazole Voriconazole Dead, 3 y 9 mt Unknown
69 M None Segmentectomy None None Alive
60 M COPD Wedge resection None Voriconazole Alive
46 F Asthma, pneumothorax Segmentectomy Voriconazole, 
posaconazole
Posaconazole Alive
45 M Tbc, ankylosing spondylitis Lobectomy and 
segmentectomy
None Voriconazole Alive
51 F Tbc, asthma Pulmectomy None Voriconazole Alive
41 M Tbc, alcohol abuse Lobectomy None None Alive
37 M Hodgkin disease, allogenic 
stem cell transplantation, 
GVHD
Wedge resection Voriconazole Posaconazole Dead, 3 y 4 mt GVHD
54 F Asthma, renal carcinoma Wedge resection, 
segmentectomy
Itraconazole, 
posaconazole
Posaconazole, 
itraconazole
Alive
58 F Prior lung abscess Segmentectomy None None Alive
61 M Rheumatoid arthritis, 
pneumothorax, diabetes
Lobectomy Voriconazole Voriconazole Alive
64 M Alfa-1-antitrypsin 
deficiency, liver 
transplantation
Lobectomy Amphotericine-B, 
voriconazole
Voriconazole Alive  
COPD, chronic obstructive pulmonary disease; tbc, tuberculosis; RA, rheumatoid arthritis; GVHD, graft-versus-host disease. 
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Aspergillus pleuritis or empyema occurred.
T h e r a p y  w i t h  a n t i f u n g a l s  w a s  d i v e r s e ,  a n d 
recommendations for medical therapy are clearly needed. 
Considering medical treatment, our cohort was too small 
for drawing conclusions regarding the efficacy of antifungal 
treatment or its length, but our study does provide valuable 
knowledge of current Finnish practice.
The current IDSA (Infectious Diseases society of 
America) guidelines, updated in 2016, recommend 
regarding CCPA: “surgical resection is an option for some 
patients with localized disease, unresponsive to medical therapy, 
including those with pan-azole-resistant Aspergillus fumigatus—
infection or persistent hemoptysis despite bronchial artery 
embolization” and state: “the outcomes from surgery are less 
favorable than those with single aspergilloma and careful risk 
assessment prior to surgical intervention is required” (19).
Indications for surgery in this study appear to be 
very similar to those in other studies haemoptysis (45%) 
being the commonest indication, as for Farid et al. (8) 
in Manchester, UK, during 1996–2011, and Muniappan 
et al. (20) in Massachusetts, USA, during 1980–2010. The 
proportion for incidental diagnosis of an aspergilloma 
in these earlier studies was considerably higher than for 
ours, being 23% and 37%. Almost all of our patients had 
preoperatively confirmed aspergilloma diagnosis or strong 
suspicion of it; only one case of ours being considered 
incidental. During the observation time 2004–2017 in our 
study the indications to operate have remained unchanged.
Recurrent infections of Aspergillus in all of these studies 
were uncommon. For Farid et al. the recurrence rate of 
Aspergillus disease was 26% (eight patients), 75% of whom 
had CCPA preoperatively, Muniappan et al. reported only 
four cases (7%) of recurrent infection and in our study 
recurrence rate was 18%. Farid et al. reported four deaths 
(13%) for any cause within five years; Muniappan et al. 
reported five-year survival of 79%. Survival in our study was 
54% (7/13) in five years, and of 6 deaths 4 were unrelated to 
Aspergillus.
In the IDSA guidelines for aspergillosis antifungal 
therapy is not routinely recommended when surgery is for 
simple aspergillomas, but they recommend that it be started 
pre- or perioperatively and continued postoperatively when 
the risk of surgical spillage of aspergilloma during surgery 
is moderate (19). The European Respiratory Society/
European Society of Clinical Microbiology and Infectious 
Diseases (ERS/ESCMID) clinical guidelines for chronic 
aspergillosis state that “when simple aspergilloma can be 
resected without spillage of fungal material adjuvant antifungal 
therapy is not required, but if spillage is anticipated, antifungal 
therapy can be administered weeks prior to the operation. No 
evidence, however, exists to support role of antifungal therapy and 
no recommendations thus can be made, and the use of antifungal 
therapy should be individualised” (3).
This study suffers from several limitations. Our number 
of patients is low, since the only operations performed 
were those with a reasonable risk of surgical complications. 
According to the literature, surgical treatment for 
Aspergillus disease is rare. It is understandable that in the 
case of non-localized disease—as most CCPA is—resection 
of one site of infection does not lead to ideal results. 
Patients suffering of progressive disease and CCPA in our 
hospital have undergone surgery only exceptionally, and 
many other studies have had a higher number of CCPA 
patients (6,8,20,21). 
The only absolute indication for surgery in aspergilloma 
is life-threatening massive haemoptysis. Since the 
aspergilloma is often present in a grossly destroyed 
lung the possibility of a difficult surgical procedure and 
complications always has to be a major consideration. An 
aspergilloma in a pulmonary cavity is a risk for haemoptysis 
and possibly for more invasive Aspergil lus  disease 
(11,22,23). The size of the aspergilloma or clinical picture 
of the disease does not predict whether life-threatening 
haemoptysis may occur (4,24). Currently, medical treatment 
of chronic Aspergillus disease only rarely leads to cure and 
risk for development of azole resistance may be increased 
when an aspergilloma exists (25). Moreover, medications 
are not very well tolerated in long-term use (26). Results of 
aspergilloma operations appear to be excellent for patients 
with localized disease, and for those whose expected risk 
for serious complications in surgery is low or relatively low. 
Good results occur for surgeries on appropriately selected 
asymptomatic patients (7,22,27). This was the case also 
in our study. These patients can often be cured, and no 
alternative curative treatment exists; if left untreated, these 
chronic infections lead to high mortality and morbidity, 
often also despite attempts to treat. 
More controversial is the question whether patients 
with non-localized disease can be helped by surgery. Will 
surgery help to limit the disease, reduce the burden of the 
infectious agent, or make it easier to control the disease 
with antifungals? In CCPA, disease progression may lead to 
emergencies with massive haemoptysis requiring emergency 
operations that cannot always be avoided despite the 
high risk from such operations. The question of timing—
considering high operative risks, and on the other hand, 
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progressive disease means high risk of an emergency—
sometimes in clinical practice leads to difficult decisions 
with no simple or ideal choices. 
Antifungal medication and its duration in surgery 
for simple aspergillomas still remain questions. Based 
on the low number and various schemes for antifungal 
medications regarding our cohort we can neither propose 
any recommendations on antifungal treatment. No 
evidence that prolonged treatment with antifungals could 
be recommended after a successful aspergilloma operation, 
seems to exist (28-30). 
Conclusions
Surgical treatment can be life-saving and increase quality of 
life in patients, suffering from haemoptysis. Also, surgery 
should be seriously considered in those whose disease 
appears to be restricted and their pulmonary reserve to be 
well preserved. 
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